Risk stratification and prognostic value of prothrombin time and activated partial thromboplastin time among COVID-19 patients

Esayas Tekle, Yemataw Gelaw, Mulat Dagnew, Aschalew Gelaw, Markos Negash, Eyuel Kassa, Segenet Bizuneh, Dessalew Wudineh, Fikir Asrie

1 Department of Medical Laboratory Sciences, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia, 2 Department of Hematology and Immunohematology, College of Medicine and Health Sciences, School of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia, 3 Department of Medical Microbiology, College of Medicine and Health Sciences, School of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia, 4 Department of Immunology and Molecular Biology, College of Medicine and Health Sciences, School of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia, 5 College of Medicine and Health Sciences, University of Gondar Comprehensive Specialized Hospital Laboratory, University of Gondar, Gondar, Ethiopia, 6 College of Medicine and Health Sciences, School of Medicine, University of Gondar, Gondar, Ethiopia, 7 Department of Medical Laboratory Sciences, Institute of Health Sciences, Mizan Tepi University, Mizan Tepi, Ethiopia

Abstract

Background

COVID-19 is a viral disease caused by a new strain of corona virus. Currently, prognosis and risk stratification of COVID-19 patients is done by the disease's clinical presentation. Therefore, identifying laboratory biomarkers for disease prognosis and risk stratification of COVID-19 patients is critical for prompt treatment. Therefore, the main objective of this study was to assess the risk stratification and prognostic value of basic coagulation parameters and factors associated with disease severity among COVID-19 patients at the Tibebe Ghion Specialized Hospital, COVID-19 treatment center, Northwest Ethiopia.

Methods

A follow-up study was conducted among conveniently recruited COVID-19 patients attended from March to June 2021. Socio-demographic and clinical data were collected using a structured questionnaire and checklist, respectively. Prothrombin time (PT) and activated partial thromboplastin time (APTPT) were analyzed by the HUMACLOT DUE PLUS® machine. Descriptive statistics were used to summarize the socio-demographic and clinical characteristics of study participants. Kruskal Wallis tests were used to compare the difference between parametric and non-parametric continuous variables, respectively. The area under the receiver operating characteristic curve (AUC) was used to evaluate the value of PT and APTPT in the risk stratification and disease prognosis of COVID-19 patients. Ordinal
logistic regression was used to identify the factors associated with disease severity and prognosis. A P-value < 0.05 was defined as statistically significant for all results.

Result

Baseline PT at a cut-off value ≥ 16.25 seconds differentiated severe COVID-19 patients from mild and moderate patients (AUC: 0.89, 95% CI: 0.83–0.95). PT also differentiated mild COVID-19 patients from moderate and severe patients at a cut-off value ≤ 15.35 seconds (AUC: 0.90, 95% CI: 0.84–0.96). Moreover, alcohol drinkers were a 3.52 times more likely chance of having severe disease than non-drinkers (95% CI: 1.41–8.81). A one-year increment in age also increased the odds of disease severity by 6% (95% CI: 3–9%). An increment of ≥ 0.65 seconds from the baseline PT predicted poor prognosis (AUC: 0.93, 0.87–0.99).

Conclusions and recommendations

Prolonged baseline PT was observed in severe COVID-19 patients. Prolonged baseline PT was also predicted to worsen prognosis. An increase from the baseline PT was associated with worsen prognosis. Therefore, PT can be used as a risk stratification and prognostic marker in COVID-19 patients.

Background

In December 2019, a cluster of severe acquired respiratory syndrome corona virus-2 (SARS-CoV-2) related acute respiratory infections occurred in Wuhan, China [1]. Because of its genomic similarity to the severe acute respiratory syndrome-related coronavirus, the virus has been dubbed SARS-CoV-2, and the disease induced by it has been dubbed coronavirus disease 2019 (COVID-19) by the World Health Organization [2, 3].

Despite a promising prognosis in mildly ill patients, several complications, including acute respiratory distress syndrome, malfunctioning of the coagulation system, and multiple organ failure can lead to death among severely ill patients [4]. Hypercoagulability is a usual pathobiological exhibition in severe COVID-19 patients [5]. Many coagulation profile have been changed in patients with COVID-19 [6, 7].

The coagulation disorder of patients with COVID-19 infection may attribute to a variety of mechanisms. One of the postulated mechanisms is that the virus binds to the angiotensin-converting enzyme-2 (ACE-2) receptor on Type II pneumocytes in the lungs and disrupts the kallikrein system. The binding of the virus to the ACE-2 receptor results in the down-regulation of ACE-2, which results in angiotensin II-mediated vascular dysfunction and a hypercoagulable state in infected people [8]. The other possible mechanism is the virus damage the endothelial and microvascular cells directly, causing inflammation and releasing excessive amounts of cytokines, all of which contribute to the development of a prothrombotic state [9–11]. Autoimmunity may be another potential player that induces antiphospholipid antibody production as verified in various viral infections [12]. Therefore, COVID-19 Patients might show coagulation anomalies which might relate to disease severity and prognosis [13, 14].

The management of critically ill patients has been incredibly hard because of the complexity and the insufficient evidence on the pathogenesis of COVID-19 [15]. Accordingly, laboratory predictors of COVID-19 progression to severe and fatal forms are urgently needed. These
predictors will allow for risk stratification of the disease and optimize the allocation of limited human and technical resources in the ongoing pandemic [16, 17]. They also play an important role in the clinical decision, treatment, and management of the COVID-19 outbreak by providing evidence-based data for medical professionals. Studies supported that around 20% to 55% of COVID-19 hospitalized patients had laboratory evidence of coagulopathy and 20% of them had severe coagulation abnormalities [18, 19]. The results provided valuable clinical and laboratory features for patients suffering from COVID-19 [20–22].

According to research findings, D-Dimer and fibrinogen levels have been recommended as best coagulation tests in risk stratification and monitoring of COVID-19 patients’ prognosis [23–25]. However, these tests are not readily available in all countries and settings. As a result, identifying the local easily accessible biomarkers such as PT and APTT can be useful to stratify disease severity and prognosis in COVID-19 patients. Moreover, currently in the Ethiopian health system, severe stratification and prognosis of COVID-19 cases are assessed and determined by using the clinical feature of the COVID-19 [26]. Therefore, the main objective of the study was to assess the prognostic and risk stratification value of PT, APTT and factors associated with disease severity among COVID-19 patients.

Materials and methods

Study design, setting and population

A follow-up study design was conducted to assess the risk stratification and prognostic value of PT APTT, and factors associated with disease severity among COVID-19 patients at the Tibebe Ghion Specialized Hospital COVID-19 treatment center from March to June 2021. The Hospital is found in Bahir Dar town which is 565 km away from Addis Ababa, the capital city of Ethiopia. The hospital is providing different medical services for more than 5 million people in the region [27]. All real-time reverse transcription polymerization chain reaction (RT-qPCR) confirmed COVID-19 patients at the Tibebe Ghion Specialized Hospital COVID-19 treatment center were the source of populations and the study populations were all RT-qPCR confirmed COVID-19 patients during the study period. But, COVID-19 patients those unable to give biological samples, those who had a predetermined coagulation abnormality and those on anticoagulant drugs therapy before the baseline coagulation determination were excluded from the study.

Sample size determination and sampling technique

The sample size was determined by using Cohen (1992)'s formula for repeated measurement for ANOVA design [28]. According to this formula, the sample size calculations depend on the effect size, power (1-β), type 1 error (α), number of groups, number of repeated measurements, and correlation of repeated measurements. Therefore, we use effect size = 0.4, which is considered a large effect size, α = 0.05, power = 0.95, number of groups = 3 (mild, moderate, and severe), number of repeated measurements = 2 (each patient will be observed at baseline and then on the 7th day), and correlation between repeated measurements = 0.5. By inserting these values into the G* Power 3.1.9.2 software, we got a total sample size of 78 (26 in each group). However, since the study was a follow-up study, a 10% loss to follow-up was considered. Therefore, the final sample size required was 86 (a minimum of 29 cases in each group). Accordingly, a sample size of 117 was used for this study (45 milds, 43 moderates, and 29 severe cases). A convenient sampling technique was used to select study participants until the minimum requirement is fulfilled (a minimum of 29 cases in each group).
Operational definitions

A coagulopathy. was defined as any abnormal prolongation and shorting of PT and/A PT. It was determined by using the reference range of PT (10–14 seconds) and APTT (26–36 seconds) at Felege Hiwot Referral Hospital Laboratory. Accordingly, Shorten PT and APTT were defined as less than 10 seconds for PT and less than 26 seconds for APTT whereas, Prolonged PT and APTT were defined as greater than 14 seconds for PT and greater than 36 seconds for APTT.

Alcohol drinker. Men who consume more than 4 drinks on any day or more than 14 drinks per week or women who consume more than 3 drinks on any day or more than 7 drinks per week [29, 30].

Mild cases. Mild clinical symptoms and no pneumonia manifestation can be found on imaging [1].

Moderate cases. Patients have symptoms like fever and respiratory tract symptoms and pneumonia manifestation can be seen in imaging [1].

Severe cases. Include those with any of the following; respiratory distress, respiratory rate \( \geq 30 \) breaths/min; oxygen saturation \( \leq 93\% \) at rest (measured by Pulse Oximetry). Patients with greater than 50% lesion progression within 24 to 48 hours in pulmonary imaging were also treated as severe cases. Moreover, Patients with respiratory failure and mechanical ventilation, shock, and complications from another organ failure that require mechanical ventilation, monitoring and treatment in the ICU were severe cases [1].

Prognosis. We did not find a clear definition of the outcome of the illness (Prognosis). Therefore, we use the change of the clinical-stage/severity to define the prognosis. Accordingly, the clinical progression (prognosis) of the patient at day seven was divided into three types: Good prognosis, no change in prognosis, and worse prognosis.

Good prognosis. Patients who were severe at admission and progressed to moderate, mild, or cured on the seventh day of hospitalization; those who were moderate at admission and progressed to mild, or cured on the seventh day of hospitalization; and those who were mild at admission and cure on the seventh day of hospitalization.

No change in prognosis. Those patients who had the same disease severity/clinical-stage at admission and on the 7th day of hospital admission (no change in disease severity).

Worse prognosis. Patients who were mild at admission and progressed to moderate or severe on the 7th day of hospital admission; patients who were moderate at admission and progressed to severe on the 7th day of hospital admission; and patients who were severe at admission and died till the 7th day of hospital admission had a worse prognosis. It also included those patients who had mild, moderate, or severe conditions at baseline and died till the 7th day of hospital admission.

Data collection procedures

Socio-demographic and clinical data collection. A pretested structured questionnaire was used as a tool for the collection of socio-demographic data. Relevant socio-demographic data (gender, age, residence, current marital status, educational status, occupation, alcohol use) and past and current medical history, including the history of chronic disease, were collected by trained nurses. A clinical data and clinical examination of patient’s vital signs like body temperature, blood pressure, pulse rate, respiratory rate, and oxygen saturation percentage were also measured and recorded on a data collection checklist. During follow-up, these vital signs were monitored according to the setup guideline and recorded by nurses on the data collection checklist.

Blood sample collection and analysis. Blood sample collection. After getting written informed consent from the study participants, 2.7 ml venous blood was collected aseptically
from the patients by an experienced medical laboratory technologist from their antecubital
vein by using a vacutainer collection system in a 3.2% tri-sodium citrate anti-coagulated test
tube. The blood specimen and anticoagulant were mixed gently. Then the platelet-poor
plasma, which was used for PT and APTT tests, was obtained by centrifuging at 1500 x g for 15
minutes. The proportion of anticoagulant and blood was 1 part sodium citrate anticoagulant
to 9 part blood. To assure quality, the collected blood was checked for proper labeling, hemoly-
sis, and clotting pre-analytically.

APTT and PT determination. The APTT and PT were determined at the Felege Hiwot
Referral Hospital Laboratory by using the HUMACLOT DUE PLUS® coagulation analyzer
(Wiesbaden, Germany). APTT was determined by mixing warmed platelet-poor plasma with
warmed APTT reagent and CaCl₂. The PT reagent, which contains lyophilized thromboplastin
of the rabbit brain, was reconstituted by mixing one vial of thromboplastin reagent with one
vial of CaCl₂ buffer solution [30].

Data quality assurance and control

Socio-demographic and clinical data quality assurance. The questionnaire was prepared
in English, translated to the Amharic language, and then translated back to English to check for
consistency. It was also pre-tested on 5% of COVID-19 patients at Debre-Markos University’s
COVID-19 treatment center for its accuracy before actual data collection. The appropriate one-
day training was given for all data collectors about the objective of the study, confidentiality issues,
study participants’ rights, consenting, and techniques of the interview before data collection.
Socio-demographic and clinical data were collected by trained and experienced nurses under the
close supervision of investigators. Vital sign measurements (blood pressure, temperature, pulse
rate, respiratory rate were measured two times and the mean was taken as the actual measure-
ment. Every collected data was checked for its completeness daily by the investigators.

Laboratory examination quality assurance. To maintain the quality of the result, pre-
analytical, analytical, and post-analytical precautions of quality and the standard operating
procedure (SOP) were strictly followed and quality control results were interpreted according
to the rules. All manufacturer instructions and SOP were strictly followed. Every specimen
collection procedure was performed aseptically to avoid contamination for both the patient and
the specimen, and the entire collected blood sample was checked for appropriate labeling,
hemolysis, clotting pre-analytically. Preventive maintenance of the instruments used (Human
Cue-due plus analyzer) was done daily, weekly, and monthly by laboratory personnel. All
reagents and materials used were checked for their expiration date, leakage, and signs of dete-
rioration (Large flaky particles in the suspension or prolonged prothrombin times on testing
normal plasma or controls may indicate product deterioration).

APTT and PT quality control. The analytical quality control of the coagulation test was
done by running normal (HEMOSTAT CONTROL PLASMA NORMAL) and abnormal qual-
ity control (HEMOSTAT CONTROL PLASMA ABNORMAL) material daily before perform-
ing tests on patient plasmas. If the results of the controls were not within their reference
ranges, patient results were considered invalid and not run/reported.

Safety management

Data collectors were provided training on COVID-19 prevention, including when to get
tested, use of personal protective equipment, and cleaning. Conditions of entry were displayed
for any customers or visitors on entry points. Hand sanitizer was provided at multiple loca-
tions throughout the workplace. Detergent/ disinfectant surface wipes were provided to clean
workstations and equipment used. Bathrooms were stocked with hand soap and paper towels
and had posters with instructions on how to wash your hands. There was frequent cleaning of
touched areas and surfaces.

Disinfectant solutions were maintained at an appropriate strength and used per the manufac-
turer’s instructions. Data collectors were wearing gloves when cleaning and washing hands thor-
oughly with soap and water before and after each activity. In general, the use of the required
personal protective equipment like a particulate respirator, mask, gown, gloves, was ensured
when contacting the patient and blood sample collection from the patient and also whenever it is
required in the process. All intervention procedures were done by sterilized and safe maneuvers.

**Data management and analysis**

The data were checked for completeness, cleaned, sorted, and categorized daily before being
entered into EpiData version 4.6 and exported to IBM SPSS version 25 for analysis. Socio-
demographic and clinical characteristics of study participants were summarized by using
descriptive statistics and then presented in tables and text. Categorical variables were given as
frequency rates and percentages; continuous variables were expressed as mean and SD
(parametric data) or mean rank, median and IQR (non-parametric data). The Shapiro-Wilk
test was used to verify the normality of the distribution of continuous variables.

The ANOVA (parametric data) and Kruskal-Wallis H-test (non-parametric data) were
used to analyze differences between groups. The post hoc test was used following the ANOVA
and Kruskal-Wallis H-test for the parameters that showed a significant difference in the groups
to determine which group was exactly the source of the difference (differences between mild,
moderate and severe stages of the disease and also between good and worse prognosis groups).

Receiver–operating characteristic (ROC) curve analysis was also performed to determine
the area under the curve (AUC) to evaluate the prognostic and stratification values of the PT
and APTT. The Youden’s index of the ROC curve was calculated to establish the cut off value
of PT and APTT that showed the best combinations of sensitivity, specificity. In the ROC
curve analysis, a parameter having the highest AUC was selected as the best prognostic and
stratification parameter in COVID-19 patient management. Ordinal logistic regression was
used to identify the factors associated with disease severity. In all statistical tests, p-
value < 0.05 was considered statistically significant.

**Ethical considerations**

The study was conducted after it was reviewed and approved by the Ethical Review Committee
of the School of Biomedical and Laboratory Sciences with a reference number SBMLS/2743/
13. A permission letter to conduct the study was also obtained from Tibebe Ghion Specialized
Referral Hospital’s chief executive officer before the commencement of the study, and the
study was as per the principles of the declaration of Helsinki II. Written informed consent was
also obtained from each study participant and any participant who was not willing to partici-
pate in the study was not forced to participate. They were also informed that all the data
obtained would be kept confidential by using codes instead of any personal identifiers and
used only for the study purpose. Moreover, all laboratory test results were communicated to
their physicians for prompt patient management.

**Results**

**Socio-demographic and behavioral characteristics**

A total of 117 COVID-19 patients were enrolled in this study at admission to the TGSH
COVID-19 treatment center. Of the included participants, 77 (65.8%) were male and 94
(80.3%) were urban residents. Education-wise, 49 (41.9%) have attained university or college, while the majority of the participants were government employees, 42 (35.9%), followed by merchants, 27 (23.1%). Of the study participants, 102 (87.2%) were married and 40 (34.2%) had alcohol consumption habits. The patients' age ranged from 20 to 88 years old with a mean age of 50.62 ± 15.39 (Table 1).

### Clinical characteristics

From the total study population, 52 (44.4%) had co-morbidity. Co-morbidity was significantly higher in moderate and severe COVID-19 patients compared to mild COVID-19 patients (24.4%, 53.5% and 62.1% of mild, moderate and severe patients, respectively) (Chi-Square p-value = 0.002). The most common co-morbidities were diabetic Mellitus and hypertension (17.1% and 14.5%, respectively). Diabetic Mellitus was significantly associated with disease severity. It was 4.4% in mild COVID-19 patients and 18.6% and 34.5% in moderate and severe COVID-19 patients, respectively (Fishers' Exact test p-value = 0.002). The most common presenting signs and symptoms were fever (57.26%), headache (59.8%), breathing difficulty (51.3%), cough (65.8%), and myalgia (51.3%). Concerning about the basic coagulation test result, 91 (77.8%) of the patients had prolonged PT and no patient had shortened PT result. The prevalence of prolonged PT was higher in moderate and severe cases (95.3% and 100%, respectively. On the other hand, shorten and prolonged APTT was observed in 54 (46.2%) and 16 (13.7%) patients, respectively. A shortened APTT was more observed in mild cases (77.8%) compare to moderate (32.6%) and severe (17.2%) cases, while prolonged APTT
was more observed in severe cases (27.6%) compared to mild (4.4%) and moderate (14.1%) cases. Eight (6.8%) of the patients died within the 7 day follow-up period. The death was significantly higher in severe cases (0%, 2.3% and 24.1% in mild, moderate, and severe cases, respectively; Fisher's Exact test p-value < 0.001). Seven (6%) patients were lost and their status was not known at day 7 (Table 2).

Table 2. Clinical characteristics of the study participants attending at the Tibebe Ghion Specialized Hospital, COVID-19 treatment center 2021 (n = 117).

| Variable                        | Category | Clinical stage | Mild (n = 45), n (%) | Moderate (n = 43), n (%) | Severe (n = 29), n (%) | Total (117), n (%) | P-value |
|---------------------------------|----------|----------------|----------------------|-------------------------|------------------------|-------------------|---------|
| Co-morbidity*                  | Yes      | 11 (24.4)      | 23 (53.5)            | 18 (62.1)               | 52 (44.4)             | 65 (55.6)         | .002a   |
|                                 | No       | 34 (75.6)      | 20 (46.5)            | 11 (37.9)               | 65 (55.6)             |                   |         |
| Type of co-morbidity            |          |                |                      |                         |                        |                   |         |
| Hypertension                    | Yes      | 3 (6.7)        | 6 (14.0)             | 8 (27.6)                | 17 (14.5)             |                   | 0.03b   |
|                                 | No       | 42 (93.3)      | 37 (86.0)            | 21 (72.4)               | 100 (85.5)            |                   |         |
| Digestive system disorder       | Yes      | 1 (2.2)        | 4 (9.3)              | 5 (17.2)                | 10 (8.5)              |                   | 0.62c   |
|                                 | No       | 44 (97.8)      | 39 (89.7)            | 24 (82.8)               | 107 (91.5)            |                   |         |
| Diabetic mellitus               | Yes      | 2 (4.4)        | 8 (18.6)             | 10 (34.5)               | 20 (17.1)             |                   | 0.002b  |
|                                 | No       | 43 (95.6)      | 35 (81.4)            | 19 (65.5)               | 97 (82.9)             |                   |         |
| Heart disease                   | Yes      | 0 (0)          | 1 (2.3)              | 2 (6.9)                 | 3 (2.6)               |                   | 0.183b  |
|                                 | No       | 45 (100)       | 42 (97.7)            | 27 (93.1)               | 114 (97.4)            |                   |         |
| Liver disease                   | Yes      | 0 (0)          | 1 (2.3)              | 0 (0)                   | 1 (0.9)               |                   | 0.615b  |
|                                 | No       | 45 (100)       | 42 (97.7)            | 29 (100)                | 116 (99.1)            |                   |         |
| Cancer                          | Yes      | 0 (0)          | 1 (2.3)              | 2 (6.9)                 | 3 (2.6)               |                   | 0.183b  |
|                                 | No       | 45 (100)       | 42 (97.7)            | 27 (93.1)               | 114 (97.4)            |                   |         |
| Tuberculosis                    | Yes      | 1 (2.2)        | 1 (2.3)              | 2 (6.9)                 | 4 (3.4)               |                   | 0.554b  |
|                                 | No       | 44 (97.8)      | 42 (97.7)            | 27 (93.1)               | 113 (96.6)            |                   |         |
| Renal disease                   | Yes      | 0 (0)          | 1 (2.3)              | 1 (3.4)                 | 2 (1.7)               |                   | 0.523b  |
|                                 | No       | 45 (100)       | 42 (97.7)            | 28 (96.6)               | 115 (98.3)            |                   |         |
| Epilepsy                        | Yes      | 2 (4.4)        | 0 (0)                | 1 (3.4)                 | 3 (2.6)               |                   | 0.464b  |
|                                 | No       | 43 (95.6)      | 43 (100)             | 28 (96.6)               | 114 (97.4)            |                   |         |
| Human Immuno virus              | Yes      | 1 (2.2)        | 3 (7.0)              | 1 (3.4)                 | 5 (4.3)               |                   | 0.538b  |
|                                 | No       | 44 (97.8)      | 40 (93.0)            | 28 (96.6)               | 112 (95.7)            |                   |         |
| Asthma                          | Yes      | 3 (6.7)        | 5 (11.6)             | 0 (0)                   | 8 (6.8)               |                   | 0.146b  |
|                                 | No       | 42 (93.3)      | 38 (88.4)            | 29 (100)                | 109 (93.2)            |                   |         |
| Other respiratory disease *     | Yes      | 1 (2.2)        | 5 (11.6)             | 4 (13.8)                | 10 (8.5)              |                   | 0.134b  |
|                                 | No       | 44 (97.8)      | 38 (88.4)            | 25 (86.2)               | 107 (91.5)            |                   |         |
| Presenting signs and symptoms   | Fever    | 9 (20.0)       | 36 (83.7)            | 22 (75.9)               | 67 (57.3)             |                   | <0.001* |
|                                 | Headache | 20 (44.4)      | 32 (81.4)            | 18 (62.0)               | 70 (59.8)             |                   | .016c   |
|                                 | Nausea   | 6 (13.3)       | 18 (41.9)            | 8 (27.6)                | 32 (27.4)             |                   | .011*   |
|                                 | Breathing difficulty | 5 (11.1)  | 30 (69.8)          | 25 (86.2)              | 60 (51.3)             |                   | <0.001* |
|                                 | Chest pain          | 6 (13.3)     | 23 (53.5)           | 18 (62.1)              | 47 (40.2)             |                   | <0.001* |
|                                 | Abdominal pain     | 12 (26.7)    | 20 (46.5)           | 11 (37.9)              | 43 (36.8)             |                   | .153*   |
|                                 | Cough             | 28 (62.2)    | 30 (69.8)           | 19 (65.5)              | 77 (65.8)             |                   | .757*   |
|                                 | Sputum production | 5 (11.1)     | 17 (39.5)           | 12 (41.4)              | 34 (29.1)             |                   | .003*   |
|                                 | Pharyngalgia      | 9 (20.0)     | 23 (53.5)           | 18 (62.01)             | 50 (42.7)             |                   | <0.001* |
|                                 | Myalgia           | 13 (28.9)    | 24 (55.8)           | 23 (79.3)              | 60 (51.3)             |                   | <0.001* |
|                                 | PT                | Normal       | 24 (53.3)           | 2 (4.7)                | 0 (0)                 | 26 (22.2)         | <0.001b |
|                                 |                  | Shorten      | 0 (0)               | 0 (0)                  | 0 (0)                 |                   |         |
|                                 |                  | Prolonged    | 21 (46.7)           | 41 (95.3)              | 29 (100)              | 91 (77.8)         |         |

(Continued)

PLOS ONE | https://doi.org/10.1371/journal.pone.0272216 | August 11, 2022 | 8 / 20
According to the current study, PT (mean rank: 30.20, 66.09 and 93.17; p-value = 0.001) and APTT (mean rank: 38.03, 66.86 and 79.88; p-value = 0.001), had significant differences between mild, moderate and severe groups, respectively. The Posthoc test of the Kruskal Wallis test also showed that PT was significantly different between mild and moderate, and mild and severe cases. It was lower in the mild case compared to moderate and severe cases (mean rank difference: -35.893 and -62.972; p-value < 0.001, respectively). It was also shown that PT was significantly lower in moderate cases compared to severe cases (mean rank difference: -27.079; p-value = 0.003). APTT was also lower in mild cases compared to moderate and severe cases (mean rank difference: -28.827 and -41.846; p-value < 0.001, respectively). However, APTT had no significant difference between moderate and severe cases (mean rank difference: -13.019; p-value = 0.330) (Table 3).

### Table 3. Comparison of baseline basic coagulation parameters between mild, moderate, and severe COVID-19 patients attending the Tibebe Ghion Specialized Hospital, COVID-19 treatment center 2021 (n = 117).

| Variable | Measurement category | Clinical stage of the disease | Kruskal-Wallis H | P-value |
|----------|----------------------|------------------------------|------------------|----------|
|          |                      | Mild (n = 45), n (%)         | Moderate (n = 43), n (%) | Severe (n = 29), n (%) |                      |
| PT, sec  | Median (IQR)         | 13.8 (13.45–15.1)           | 16.0 (15.4–17)    | 18.3 (16.7–20.3) | 63.796              | <.001*** |
|          | Mean rank            | 30.20                       | 66.09            | 93.17     |                      |          |
| APTT, sec| Median (IQR)         | 23.7 (22.1–25.25)           | 28.6 (25–31.5)   | 29.8 (26.2–36.65) | 30.499              | <.001*** |
|          | Mean rank            | 38.03                       | 66.86            | 79.88     |                      |          |

### Table 2. (Continued)

| Variable | Category | Mild stage | Moderate stage | Severe stage | P-value |
|----------|----------|------------|---------------|--------------|---------|
|          |          | (n = 45), n (%) |        |        | Total (117), n (%) |       |
| APTT     | Normal   | 8 (17.8)   | 23 (53.5)    | 16 (55.2)   | 47 (40.2) | <0.001b |
|          | Shorten  | 35 (77.8)  | 14 (32.6)    | 5 (17.2)    | 54 (46.2) |         |
|          | Prolonged| 2 (4.4)    | 6 (14.0)     | 8 (27.6)    | 16 (13.7) |         |
| Patient status at day 7 | Healed | 16 (35.6) | 6 (14.0) | 1 (3.4) | 23 (19.7) | <0.001b |
|          | On treatment | 27 (60.0) | 31 (72.1) | 21 (72.4) | 79 (67.5) |         |
|          | Died      | 0 (0)      | 1 (2.3)      | 7 (24.1)    | 8 (6.8)   |         |
|          | Lost      | 2 (4.4)    | 5 (11.6)     | 0           | 7 (6.0)   |         |

#: presence of one or more of the disease listed in the type of co-morbidity
a: Pearson chi-square P-value
b: fisher exact test P-value
*: bronchitis and allergic rhinitis

Risk stratification values of baseline basic coagulation tests

According to the current study, PT (mean rank: 30.20, 66.09 and 93.17; p-value = 0.001) and APTT (mean rank: 38.03, 66.86 and 79.88; p-value = 0.001), had significant differences between mild, moderate and severe groups, respectively. The Posthoc test of the Kruskal Wallis test also showed that PT was significantly different between mild and moderate, and mild and severe cases. It was lower in the mild case compared to moderate and severe cases (mean rank difference: -35.893 and -62.972; p-value < 0.001, respectively). It was also shown that PT was significantly lower in moderate cases compared to severe cases (mean rank difference: -27.079; p-value = 0.003). APTT was also lower in mild cases compared to moderate and severe cases (mean rank difference: -28.827 and -41.846; p-value < 0.001, respectively). However, APTT had no significant difference between moderate and severe cases (mean rank difference: -13.019; p-value = 0.330) (Table 3).
According to the ROC curve analysis, PT at a cut-off point of \( \geq 16.25 \) seconds can differentiate severe COVID-19 patients from mild and moderate COVID-19 patients with a sensitivity of 89.7%, specificity of 76.1%, PPV of 61.7%, and NPV of 100% (AUC: 0.89, 95% CI: 0.83–0.95). PT can also differentiate mild COVID-19 patients from moderate and severe COVID-19 patients at a cut-off point of \( \leq 15.35 \) seconds with a sensitivity of 82.2%, specificity of 86.1%, PPV of 95.75% and NPV of 100% (AUC: 0.90, 95% CI: 0.84–0.96). APTT can differentiate severe COVID-19 patients from mild and moderate COVID-19 patients at a cut-off value of \( \geq 25.5 \) seconds with a sensitivity of 89.7%, specificity of 54.5%, PPV of 43.94% and NPV of 100% (AUC: 0.74, 95% CI: 0.64–0.83). At a cut-off value of \( \leq 25.35 \) seconds, it can also distinguish mild COVID-19 patients from moderate and severe COVID-19 patients, with a sensitivity of 77.8%, specificity of 79.2%, PPV of 90% and NPV of 100% (AUC: 0.79, 95% CI: 0.7–0.88) (Table 4).

Prognostic value of baseline prothrombin time

Severe COVID-19 patients were lost during the follow up period and their clinical stage at day 7 was not known. Therefore, the prognostic value baseline PT was assessed only for 110 study participant. It had significant differences between good prognosis, no change in prognosis, and worse prognosis groups (mean rank: 56.21, 44.82, and 74.56; p-value = 0.005, respectively). The Posthoc test of the Kruskal Wallis test also showed that PT was significantly different between patients with worse prognosis and no change in prognosis (mean rank difference: 29.74; p-value = .004). According to the ROC curve analysis, a baseline PT result of \( \geq 16.15 \) seconds could predict a poor prognosis with a sensitivity of 81.3% and specificity of 63% (AUC: 0.72, 95% CI: 0.57–0.87). However, PT had a low predictive value of COVID-19 patients with a good prognosis at a cut-off value of \( \geq 16.05 \) seconds (AUC: 0.47, 95% CI: 0.36–0.58) (Tables 5 and 6).

### Table 4. The risk stratification values of baseline PT and APTT among COVID-19 patients attending at the Tibebe Ghion Specialized Hospital, COVID-19 treatment center 2021 (n = 117).

| Parameter | Category | AUC (95% CI) | Cut-off value | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Youden Index |
|-----------|----------|--------------|---------------|----------------|----------------|---------|---------|--------------|
| PT, Sec   | Severe from others | 0.89 (0.83–0.95) | \( \geq 16.25 \) | 89.7 | 76.1 | 61.7 | 100 | 0.658 |
|            | Mild from others | 0.90 (0.84–0.96) | \( \leq 15.35 \) | 82.2 | 86.1 | 95.75 | 100 | 0.683 |
| APTT, sec | Severe from others | 0.74 (0.64–0.83) | \( \geq 25.5 \) | 89.7 | 54.5 | 43.94 | 100 | 0.442 |
|            | Mild from others | 0.79 (0.7–0.88) | \( \leq 25.35 \) | 77.8 | 79.2 | 90 | 100 | 0.57 |

### Table 5. Comparison of baseline basic coagulation tests between patient prognosis among COVID-19 patients attending at the Tibebe Ghion Specialized Hospital, COVID-19 treatment center 2021 (n = 110).

| Variable | Measurement category | Prognosis of the patient | P-value |
|----------|----------------------|--------------------------|---------|
|          |                      | Good (n = 55)            | No change (n = 39) | Worse (n = 16) | Kruskal- Wallis H |
| PT, sec  | Median (IQR)         | 15.8 (14.88–17.13)      | 15 (13.65–16.45) | 17 (16.25–20.75) | 10.73 | .005 |
|          | Mean rank            | 56.21                    | 44.82                | 74.56                |       | |
| APTT, sec| Median (IQR)         | 27.2 (24–31.93)          | 24.9 (22.6–32.6)    | 29.6 (25.77–32.3)   | 3.21  | .201 |
|          | Mean rank            | 54.99                    | 49.55                | 65.99                |       | |

Posthoc test of Kruskal Wallis H

| severity (I) | severity (J) | Mean rank difference (I–J) | P-value | Adjusted P-value |
|--------------|--------------|----------------------------|---------|-----------------|
| PT Good      | No change    | 11.39                      | 0.082   | 0.247           |
|              | Worse        | -18.35                     | 0.041   | 0.124           |
|              | No change    | 29.74                      | .001    | 0.004           |

https://doi.org/10.1371/journal.pone.0272216.t004

https://doi.org/10.1371/journal.pone.0272216.t005
The prognostic value of a gradual change of prothrombin time and activated partial thromboplastin time

Seventeen COVID-19 patients had no a day 7 PT and APTT due to 7 were lost, 8 were died emedtily after they gave the baseline blood sample and 2 samples rejected due to low volume. Therefore, only 100 COVID-19 patients were had day 7 PT and APTT and the prognostic value of a gradual change of PT and APTT was assessed using 100 patients. The result showed that patients who had a good prognosis had a low PT result at day 7 compared to baseline PT result. On average, 1.66 (95% CI: -2.23 to -1.09) second was decreased at the 7th day PT compare to baseline PT in patients who had a good prognosis. There was also a slight decrement between the 7th day and baseline PT in patients who had no change in prognosis. But it was statistically insignificant (-0.09 second; 95% CI: -0.79 to 0.61). On the other hand patients with a worse prognosis showed a significant increment in PT result at day 7 compare to the baseline PT; in average, 3.00 (95% CI: 1.24 to 4.76) seconds was increased from the baseline PT. However, the APTT result was not significantly changed with patient prognosis (Fig 1 and S1 Table).

According to the ROC curve analysis, an increase of ≥ 0.65 seconds from the baseline PT result indicated a worse prognosis with a sensitivity of 100% and a specificity of 79.3% (AUC: 0.93; 95% CI: 0.87–0.99). It also revealed that a mean decrement of ≥ 0.4 seconds from the baseline PT result indicated a good prognosis, with a sensitivity of 78% and specificity of 64% (AUC: 0.75; 95% CI: 0.65–0.84) (Table 7, Figs 2 and 3).

Factors associated with disease severity and prognosis

In the ordinal logistic regression analysis, COVID-19 disease severity was found to be associated with PT, age and alcohol consumption. A one-second increment in PT increased the odds

---

**Table 6. Prognostic values of baseline basic coagulation tests among COVID-19 patients attending at the Tibebe Ghion Specialized Hospital, COVID-19 treatment center 2021 (n = 110).**

| Parameter | Category of prognosis | AUC (95% CI) | Cut-off value | Sensitivity (%) | Specificity (%) | Youden Index |
|-----------|-----------------------|--------------|---------------|----------------|----------------|--------------|
| PT, Sec   | Worse from others     | 0.72 (0.57–0.87) | ≥ 16.15      | 81.3           | 63             | 0.443        |
|           | Good from others      | 0.47 (0.36–0.58) | ≤ 16.05      | 60             | 48.3           | 0.083        |

https://doi.org/10.1371/journal.pone.0272216.t006

---

**Fig 1. Mean prothrombin time change associated with disease prognosis (7th day—baseline PT).**

https://doi.org/10.1371/journal.pone.0272216.g001
of COVID-19 severity by 2.47 times more likely (95% CI: 1.81–3.37). The result also showed that one year increment of the patient’s age increased the severity of COVID-19 disease by 6% (95% CI: 3–9%). The odds of COVID-19 disease severity were 3.52 times more likely among alcohol drinkers compared to non-drinkers (95% CI: 1.41–8.81). However, APTT (AOR: 0.99; 95% CI: 0.90–1.08) and co-morbidity (AOR: 1.96; 95% CI: 0.80–4.80) were not significantly associated with disease severity.

On the other hand, the ordinal logistic regression showed that only the PT mean difference was significantly associated with a worse prognosis of COVID-19. A one-second increment from the baseline PT to the 7th day PT increased the odds of a worse prognosis by 1.70 times more likely (95% CI: 1.37–2.12). However, age (AOR: 1.01; 95% CI: 0.99–1.04), alcohol consumption (AOR: 0.50; 95% CI 0.19–1.27), and co-morbidity (AOR: 1.04; 95% CI: 0.43–2.53) were not significantly associated with worsen prognosis of COVID-19 patients (Table 8).

Table 7. The prognostic value of a gradual change of prothrombin time over the 7th-day among COVID-19 patients attending the Tibebe Ghion Specialized Hospital, COVID-19 treatment center 2021 (n = 100).

| Parameter           | Prognosis category | AUC (95% CI)      | Cut-off point | Sensitivity (%) | Specificity (%) | Youden Index |
|---------------------|--------------------|-------------------|---------------|-----------------|-----------------|--------------|
| PT mean difference  | Worse from others  | 0.93 (0.87–0.99)  | ≥ 0.65        | 100             | 79.3            | 0.793        |
|                     | Good from others   | 0.75 (0.65–0.84)  | ≤ -0.4        | 78              | 64              | 0.42         |

Fig 2. The ROC curve of the gradual change of prothrombin time over the 7th days for prediction of worse prognosis (n = 100).
Discussion

Thrombotic complications appear to be a major concern among COVID-19 patients [19, 31]. Therefore, in patients confirmed to have COVID-19, useful prognostic information could be obtained by testing basic coagulation parameters including PT, APTT [32].

Various viral infections, such as SARS-Co and influenza virus infection, have been linked to coagulation disorders [33–35]. According to the current study, most (77.8%) of the COVID-19 patients had prolonged PT. The problem was high in moderate and severe COVID-19 patients (95.3% and 100% of the moderate and severe patients, respectively). On

Table 8. Factors associated with COVID-19 disease severity among COVID-19 patients attending the Tibebe Ghion Specialized Hospital, COVID-19 treatment center 2021.

| Risk factors of disease severity (n = 117) | Adjusted Odds ratio (95% CI) | P-value |
|------------------------------------------|-----------------------------|---------|
| PT                                       | 2.47 (1.81–3.37)            | 0.000   |
| APTT                                     | 0.99 (0.90–1.08)            | 0.798   |
| Age                                      | 1.06 (1.03–1.09)            | 0.000   |
| Alcohol use                              | 3.52 (1.41–8.81)            | 0.007   |
| Co-morbidity                             | 1.96 (0.80–4.80)            | 0.140   |

Table 8. Factors associated with COVID-19 disease prognosis (n = 100)

| Risk factors of disease prognosis (n = 100) | Adjusted Odds ratio (95% CI) | P-value |
|--------------------------------------------|-----------------------------|---------|
| PT change in second                        | 1.70 (1.37–2.12)            | 0.000   |
| Age in year                                | 1.01 (0.99–1.04)            | 0.300   |
| Alcohol use                                | 0.50 (0.19–1.27)            | 0.143   |
| Co-morbidity                               | 1.04 (0.43–2.53)            | 0.930   |
the other hand, only 13.7% of COVID-19 patients were showed a prolonged APTT and it was more common in severe COVID-19 patients compared to moderate and mild COVID-19 patients. This finding was supported by the study done in the Islamic Republic of Iran which reported that prolonged PT was common, but not APTT [32]. The finding was also showed that a shortened APTT was found in 46.2% of COVID-19 patients and it was more common in mild cases (77.8% of the mild cases) compared to moderate and severe cases. This might be due to that in the early phase of the disease, more coagulation proteins might be activated and circulated in the peripheral blood and caused a shortened APTT in vitro. However, as the disease advanced these proteins might be consumed and no more shorten APTT might be observed rather prolonged APTT might be observed. In addition, as the severity increases, there might be liver damage which is responsible for the production of most coagulation proteins. A past report showed that 60% of patients developed liver damage due to the SARS epidemic [36]. COVID-19 also belongs to the same coronavirus family which may cause liver injury [37]. The study done in China found that 41.0% and 5.0% of the COVID-19 patients had abnormal liver function tests and liver injury at admission and after 2 weeks of hospitalization, patients with abnormal liver function tests and liver injury increased to 76.3% and 21.5% respectively [38]. The early affected coagulation protein in liver damage is factor VII due to short half-life in the circulation and this causes an early prolonged PT than APTT [39]. This finding was similar to the study findings done in Millennium COVID-19 care and treatment center, Addis Ababa, Ethiopia [40] and Renmin Hospital of Wuhan University [41].

The present study demonstrated that PT at admission had a statistical significance difference between mild, moderate and severe COVID-19 patients (p-value = 0.001). The Posthoc test analysis of the Kruskal Wallis test revealed that PT was significantly lower in mild COVID-19 patients compared to moderate and severe COVID-19 patients (p-value < 0.001). Prothrombin time was also significantly lower in moderate COVID-19 patients compared to severe COVID-19 patients (p-value: 0.003). The ordinal logistic regression analysis demonstrated that a one-second increase in PT increased the odds of the severity of the disease by 2.47 times (95% CI: 1.8, 3.55). The prolongation of PT among patients with the more severe disease might be due to the consumption of coagulation factors. Prothrombin time evaluates the integrity of the extrinsic and common pathways of coagulation and can be affected by the extrinsic and the final common pathway [41–43]. The activation and increment of the coagulation markers have been reported in many viral infections. The increase of the coagulation markers indicates a balance shifted to a procoagulant state. This ultimately leads to the consumption or loss of clotting factors, organ failure and endothelial cell dysfunction [35]. This finding was consistent with previous studies done in China [44–46]. Moreover, other studies demonstrated that prolonged PT was associated with an increased risk of death [24, 45, 47].

On the other hand, other investigations conducted in China [46, 48], and Ireland [49] were contradicted the current findings. They reported that the admission PT had no significant difference between severe and mild COVID-19 patients. The discrepancy could be due to sample size, racial origin, or the usage of anticoagulant medications. There was a sample size and study participant difference between the current study and study done by Guang et al. Study participants in Guang et al. study also took anticoagulant medications before the baseline blood samples were taken, unlike those in our study [46]. However, the discrepancy between the results of this study and those of Huan et al. in China [48] and Helen et al. in Ireland [49] might be due to racial differences in the study populations. Some studies showed that race/ethnicity has major effects on thrombotic risk, with coagulopathy [49–51].

In the ROC curve analysis, baseline PT, at a cut off value of ≥16.25 seconds, had an AUC of 0.89 [95% CI: 0.83–0.95] to stratify severe COVID-19 patients from the mild and moderate cases with a sensitivity of 89.7%, specificity of 76.1%, PPV of 61.7%, and NPV of 100%. It can
also differentiate mild COVID-19 patients from moderate and severe COVID-19 patients at a cut-off point ≤ 15.35 seconds with a sensitivity of 82.2%, specificity of 86.1%, PPV of 95.745% and NPV of 100% (AUC: 0.90, 95% CI: 0.841–0.959). This finding was supported by the study conducted in China. According to this study, PT (AUC = 0.90) had a good predictive value to stratify mild versus severe/critical patients [46]. Similar multiple studies support that baseline/admission PT had a good risk stratification value among COVID-19 patients [14, 32, 45, 46, 52–55].

The current study also showed that APTT at admission was significantly different between mild, moderate and severe COVID-19 patients (p-value = 0.001). in the Posthoc test analysis, APTT was significantly lower in mild COVID-19 patients compared to moderate and severe COVID-19 patients (p-value < 0.001). However, in the ordinal logistic regression analysis, controlling the confounding factors, APTT was not associated with disease severity (95% CI: 0.88, 1.07). The current finding was consistent with previous research done in China [44, 48]. However, it was inconsistent with other studies conducted in China [45, 46, 48]. The main source of disagreement might be sample size.

The ROC curve in the current study showed that admission APTT cut-off value of ≥ 25.5 seconds had AUC of 0.737 (95% CI; 0.64–0.83) to differentiate severe COVID-19 patients from mild and moderate with a sensitivity of 89.7%, specificity of 54.5%, PPV of 43.94% and NPV of 100%. At a cut off value of ≤ 25.35 seconds, it can also distinguish mild COVID-19 patients from moderate and severe COVID-19 patients, with a sensitivity of 79.2%, specificity of 90% and NPV of 100% (AUC: 0.79, 95% CI: 0.7–0.88). Likewise, a study conducted in China showed that APTT at (AUC = 0.75) had good stratification ability in mild vs. severe/critical patients [46].

In the ordinal regression analysis, alcohol consumption and patient age were significantly associated with disease severity. The odds of severity were 3.52 times more likely in alcohol drinkers compared to non-drinkers (95% CI: 1.41–8.81). One systematic review and meta-analysis showed that alcohol consumption was significantly increased the risk of acute respiratory distress syndrome [56]. Acute respiratory distress syndrome is a common clinical manifestation of COVID-19 patients [57]. Alcohol can increase the risk of developing acute respiratory distress syndrome through various mechanisms, including alveolar epithelium dysfunction, alcohol-induced oxidative stress and interference of alveolar macrophage function [58]. A study showed that hospitalized patients with pneumonia, having an alcohol-related diagnosis was associated with a greater likelihood of admission and longer length of stay [59]. Chronic alcohol consumption can also induce cilia dysfunction in airways that reduce their ability to clear bacteria and viruses [58].

Additionally, the current study revealed that one year increment in patient age was increased the odds of severity by 6% (95 CI: 3–9%). Recent studies also revealed that the severity of COVID-19 was high in older age groups [31, 55, 60–63]. Aging changes the immune system, mitochondrial function, and hormone levels. The intact function of the immune system and mitochondria is critical to protection against severe COVID-19. Moreover, Co-morbidities associated with old age, and poor nutrition caused old people at additional risk of COVID-19 [64].

The results of the current study also showed that PT was substantially different between patients with a good prognosis, no change in prognosis, and a poor prognosis (p-value = 0.005). It was longer among COVID-19 patients with a worse prognosis compared to those who had no change in prognosis (p-value 0.004). moreover, the ROC curve analysis revealed that a baseline PT result ≥ 16.25 seconds predicted poor prognosis with a sensitivity of 81.3% and a specificity of 63% (AUC: 0.718, 95% CI: 0.571–0.865). This finding was similar to the findings done by Long et al and Jin et al in China [46, 54].
The current study also assessed the value of the gradual change of PT over the 7 days with patient prognosis. Accordingly, PT had a statistically significant gradual change over the 7 days between patients with a good prognosis and those with a worse prognosis. Patients with a good prognosis were showed a gradual decrement in PT (-1.66 second; 95% CI: -2.23 to -1.09), while patients with worsened prognosis had a significantly gradual raised PT result (3.00 seconds; 95% CI: 1.24 to 4.76). On the other hand, patients that did not show a change in their clinical stage/prognosis over the 7 days had no significant change in PT (-0.09 second; 95% CI: -0.79 to 0.61). The ROC curve analysis also revealed that a mean of ≥ 0.65 seconds increment from the baseline PT result predicted a worse prognosis with a sensitivity of 100% and specificity of 79.3% (AUC: 0.93; 95% CI: 0.87–0.99). It also showed that a mean of ≥ 0.4 seconds decrement from the baseline PT result predicted a good prognosis with a sensitivity of 78% and specificity of 64% (AUC: 0.75; 95% CI: 0.65–0.84). In other words, a gradual one-second rise in PT over the first seven days, increased the odds of worse prognosis by 1.65 times (95% CI: 1.33, 2.04). This finding was supported by a study conducted in Chinese patients which showed a gradual rise in PT over the first seven days following admission was associated with patient death, and it remained stable in surviving COVID19 patients [14]. In addition, a study conducted by Danying et al. in China reported that as the severity of the disease increased, PT also increased significantly [45]. However, contrary to the current findings, the study conducted in Finland by Helen et al. found that there was no significant increment in PT in those patients who had a bad prognosis [49]. The discrepancy might be due to the difference in the study population (predominantly Caucasian) and that their patients were already taking low-molecular-weight heparin when they were admitted. Low-molecular-weight heparin is an anticoagulant used in the prevention of blood clots and venous thromboembolism and it shorten the PT by reducing inflammatory reaction [65, 66].

**Strengths and limitations**

This study could provide the value coagulation parameters concerning the prognostic and risk stratification among COVID-19 patients. However, the current study had limitations. First, this study was a single-center follow-up study, and the results may not be representative. Second, the sample size was relatively low. Third, we only collected blood coagulation tests at admission and on the 7th day after hospitalization, which may not accurately reflect the continuous dynamic changes in coagulation and prognosis of COVID-19. A multicenter study with larger sample size is needed to verify the current findings.

**Conclusion**

Dynamically monitoring coagulation parameters such as PT and APTT might help in stratifying and predicting severity and COVID-19 patient outcomes. Prolongation of baseline PT can be used as risk stratification and prediction of COVID-19 patients’ outcomes. A gradual rise in PT over the days was also associated with a worse prognosis. Moreover, PT was the better basic coagulation test than APTT to use as risk stratification and prognostic marker. Hence, regularly assessing and screening the coagulation profile of patients with COVID-19 is important for prompt management and minimizing the worse prognosis of COVID-19 patients. COVID-19 disease severity was also associated with older age. We recommend clinicians and policymakers consider the utilization of PT for risk stratification among COVID-19 patients. It is also recommended that more attention be given to patients with older age groups and patients with alcohol consumption habits, as severity is found to be associated with age and alcohol consumption. Furthermore, multicenter studies with large sample sizes are required to
verify the prognostic and risk stratification values of basic coagulation parameters among COVID-19 patients.

**Supporting information**

S1 Table. Comparison of the change of baseline basic coagulation with patient prognosis. (DOCX)

**Acknowledgments**

We wish to extend our sincere thanks and gratitude to the Tibebe Ghion Comprehensive Specialized Hospital staff for their willingness and support during data collection; Felege Hiwot Referral Hospital and the Amhara Public Health Institute for their support in coagulation laboratory analysis. Finally, many thanks were given to all study participants for their willingness to participate and for providing the necessary information during the data collection.

**Author Contributions**

**Conceptualization:** Esayas Tekle, Yemataw Gelaw, Mulat Dagnew, Segenet Bizuneh, Dessalew Wudineh, Fikir Asrie.

**Data curation:** Esayas Tekle, Yemataw Gelaw, Mulat Dagnew, Dessalew Wudineh, Fikir Asrie.

**Formal analysis:** Esayas Tekle, Yemataw Gelaw, Mulat Dagnew, Aschalew Gelaw, Markos Negash, Dessalew Wudineh, Fikir Asrie.

**Investigation:** Yemataw Gelaw, Markos Negash, Eyuel Kassa, Dessalew Wudineh, Fikir Asrie.

**Methodology:** Esayas Tekle, Yemataw Gelaw, Mulat Dagnew, Aschalew Gelaw, Markos Negash, Eyuel Kassa, Segenet Bizuneh, Fikir Asrie.

**Software:** Aschalew Gelaw, Markos Negash, Fikir Asrie.

**Supervision:** Segenet Bizuneh, Fikir Asrie.

**Validation:** Fikir Asrie.

**Writing – original draft:** Esayas Tekle, Aschalew Gelaw, Markos Negash, Segenet Bizuneh.

**Writing – review & editing:** Yemataw Gelaw, Mulat Dagnew, Aschalew Gelaw, Markos Negash, Eyuel Kassa, Segenet Bizuneh, Dessalew Wudineh, Fikir Asrie.

**References**

1. Wei P.-F., Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chinese medical journal, 2020. 133(9): p. 1087–1095. https://doi.org/10.1097/CM9.0000000000000819 PMID: 32358325

2. Wang L., et al., Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. International Journal of Antimicrobial Agents, 2020. 55(6).

3. King A.M., et al., Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2018). Archives of virology, 2018. 163(9): p. 2601–2631. https://doi.org/10.1007/s00705-018-3847-1 PMID: 29754305

4. Huang C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 2020. 395(10223): p. 497–506.

5. Cao W. and Li T., COVID-19: towards understanding of pathogenesis. Cell Res, 2020. 30(5): p. 367–369. https://doi.org/10.1038/s41422-020-0327-4 PMID: 32346073

6. Chen N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet, 2020. 395(10223): p. 507–513. https://doi.org/10.1016/S0140-6736(20)30211-7 PMID: 32007143
7. Kollias A., et al., Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. British journal of haematology, 2020. 189(5): p. 846–847. https://doi.org/10.1111/bjh.16727 PMID: 32304577
8. van Nieuwkoop C., COVID-19 associated pulmonary thrombosis. Thrombosis Research, 2020. 191: p. 151. https://doi.org/10.1016/j.thromres.2020.04.042 PMID: 32386985
9. Ackermann M., et al., Pulmonary vascular endotheliitis, thrombosis, and angiogenesis in Covid-19. New England Journal of Medicine, 2020. 383(2): p. 120–128. https://doi.org/10.1056/NEJMoa2015432 PMID: 32437596
10. Varga Z., et al., Endothelial cell infection and endotheliitis in COVID-19. The Lancet, 2020. 395(10124): p. 1417–1418. https://doi.org/10.1056/NEJMoa2011430 PMID: 32202248
11. Du F., Liu B., and Zhang S., COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. Journal of thrombosis and thrombolysis, 2021. 51(2): p. 313–329. https://doi.org/10.1007/s11239-020-02224-2 PMID: 32676883
12. Lazzaroni M.G., et al., Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. Blood Rev, 2021. 46: p. 100745. https://doi.org/10.1016/j.blre.2020.100745 PMID: 32868115
13. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 2020. 395: p. 1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3 PMID: 32171067
14. Tang N., et al., Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis 2020. 18(4): p. 844–847. https://doi.org/10.1111/jth.14768 PMID: 32286245
15. Eshfazli R.M., et al., Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: a meta-analysis of 6320 patients. PLOS ONE, 2020. 15(8): p. 1–20. https://doi.org/10.1371/journal.pone.0238160 PMID: 32822430
16. Younis N.G., et al., Hematological changes among Coronavirus-19 patients: a longitudinal study. Systematic Reviews in Pharmacy, 2020. 11(5): p. 862–866.
17. Henry B.M., et al., Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM), 2020. 58(7): p. 1021–1028. https://doi.org/10.1515/cclm-2020-0369 PMID: 32286245
18. Zhai Z., et al., Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thrombosis and haemostasis, 2020. 120(06): p. 937–948. https://doi.org/10.1155/s-0040-1710019 PMID: 32310685
19. Lee S.G., Fralick M., and Sholzberg M., Coagulopathy associated with COVID-19. CMAJ: Canadian Medical Association Journal, 2020. 192(21): p. E583. https://doi.org/10.1503/cmaj.200685 PMID: 32357997
20. Bastug A., et al., Clinical and laboratory features of COVID-19: Predictors of severe prognosis. Int Immunopharmacol, 2020. 88: p. 106950. https://doi.org/10.1016/j.intimp.2020.106950 PMID: 32919217
21. Puah S.H., et al., Clinical features and predictors of severity in COVID-19 patients with critical illness in Singapore. Scientific Reports, 2021. 11(1): p. 7477. https://doi.org/10.1038/s41598-021-81377-3 PMID: 33820944
22. Sharma J., et al., Clinical Predictors of COVID-19 Severity and Mortality: A Perspective. Frontiers in Cellular and Infection Microbiology, 2021. 11. https://doi.org/10.3389/fcimb.2021.674277 PMID: 34760713
23. Statsenko Y., et al., Prediction of COVID-19 severity using laboratory findings on admission: informative values, thresholds, ML model performance. BMJ Open, 2021. 11(2): p. e044500. https://doi.org/10.1136/bmjopen-2020-044500 PMID: 33637550
24. Al-Samkari H., et al., COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, 2020. 136(4): p. 489–500. https://doi.org/10.1182/blood.2020006520 PMID: 32492712
25. Al-Otair H., et al., The Level of vWF Antigen and Coagulation Markers in Hospitalized Patients with Covid-19. Journal of blood medicine, 2021. 12: p. 809. https://doi.org/10.2147/JBM.S318940 PMID: 34512061
26. Patel A.J., et al., Capillary versus venous haemoglobin determination in the assessment of healthy blood donors. Vox Sang, 2013. 104(317–323). https://doi.org/10.1111/vox.12006 PMID: 23294266
27. Wassihun B. and Deribe L., Prevalence of disrespect and abuse of women during child birth and associated factors in Bahir Dar town, Ethiopia. 2018. 40: p. e2018029. https://doi.org/10.4178/epih.e2018029 PMID: 30056644
28. Karadag O. and Aktas S., Optimal sample size determination for ANOVA designs. 2011.
29. Control C.f.D. and Prevention, Alcohol use and your health. Fact sheet. Available at: https://www.cdc.gov/alcohol/pdfs/alcoholyourhealth.pdf. Accessed date February 2014. 8.
30. Bidira K., Tamiru D., and Belachew T., Anthropometric failures and its associated factors among pre-school-aged children in a rural community in southwest Ethiopia. Plos one, 2021. 16(11): p. e0260368. https://doi.org/10.1371/journal.pone.0260368 PMID: 34843555
31. Guan W.-J., et al., Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 2020. 382(18): p. 1708–1720. https://doi.org/10.1056/NEJMoa2002032 PMID: 32109013
32. Sayad B. and Rahimi Z., Blood coagulation parameters in patients with severe COVID-19 from Kermanshah Province, Islamic Republic of Iran. Eastern Mediterranean Health Journal, 2020. 26(9): p. 999–1004. https://doi.org/10.26719/emhj.20.105 PMID: 33047789
33. Singh S.K. Middle East respiratory syndrome virus pathogenesis. in Seminars in respiratory and critical care medicine. 2016. Thieme Medical Publishers.
34. Goeijenbier M., et al., Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets. BMC microbiology, 2014. 14(1): p. 1–13. https://doi.org/10.1186/1471-2180-14-134 PMID: 24884666
35. Goeijenbier M., et al., Viral infections and mechanisms of thrombosis and bleeding. Journal of medical virology, 2012. 84(10): p. 1680–1696.
36. Jothimani D., et al., COVID-19 and the liver. Journal of Hepatology, 2020. 73(5): p. 1231–1240. https://doi.org/10.1016/j.jhep.2020.06.006 PMID: 32553666
37. Sharma A., et al., Liver disease and outcomes among COVID-19 hospitalized patients—a systematic review and meta-analysis. Annals of hepatology, 2021. 21: p. 100273. https://doi.org/10.1016/j.aohep.2020.10.001 PMID: 33075578
38. Yu D., et al., Liver injury in COVID-19: clinical features and treatment management. Virology Journal, 2021. 18(1): p. 121. https://doi.org/10.1186/s12985-021-01593-1 PMID: 34108015
39. Nigatu G., et al., Prevalence and associated factors of underweight among children 6–59 months of age in Takusa district, Northwest Ethiopia. International journal for equity in health, 2018. 17(1): p. 1–8.
40. Araya S., et al., Blood coagulation parameter abnormalities in hospitalized patients with confirmed COVID-19 in Ethiopia. Plos one, 2021. 16(6): p. e0252939. https://doi.org/10.1371/journal.pone.0252939 PMID: 34153056
41. Wang L., et al., Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients. World J Clin Cases, 2020. 8(19): p. 4370–4379. https://doi.org/10.12998/wjcc.v8.i19.4370 PMID: 33083396
42. Yang R. and Moosavi L., Prothrombin time. StatPearls Publishing; Last Update: March 9, 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544269/. Accessed date June 2022.
43. Chee Y., Coagulation. The journal of the Royal College of Physicians of Edinburgh, 2014. 44(1): p. 42–45. https://doi.org/10.4997/JRCE.2014.110 PMID: 24995447
44. Han H., et al., Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clinical Chemistry and Laboratory Medicine (CCLM), 2020. 58(7): p. 1116–1120. https://doi.org/10.1515/cclm-2020-0188 PMID: 32172226
45. Liao D., et al., Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. The Lancet Haematology, 2020. 7(9): p. e671–e678. https://doi.org/10.1016/S2352-3026(20)30217-9 PMID: 32659214
46. Fogarty H., et al., COVID19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020. 189(6): p. 1044–1049. https://doi.org/10.1111/bjh.16749 PMID: 32330308
50. Frydman G.H., et al., Coagulation Status and Venous Thromboembolism Risk in African Americans: A Potential Risk Factor in COVID-19. Clinical and Applied Thrombosis/Hemostasis, 2020. 26: p. 1076029620943671. https://doi.org/10.1177/1076029620943671 PMID: 32702995

51. Chaudhary R., et al., Race-related disparities in COVID-19 thrombotic outcomes: beyond social and economic explanations. EClinicalMedicine, 2020. 29. https://doi.org/10.1016/j.eclinm.2020.100647 PMID: 33251501

52. Luo H.C., et al., Characteristics of coagulation alteration in patients with COVID-19. 2021. 100(1): p. 45–52. https://doi.org/10.1007/s00277-020-04305-x PMID: 33079220

53. Jin S., et al., Prevalence and impact of coagulation dysfunction in COVID-19 in China: a meta-analysis. Thrombosis and haemostasis, 2020. 120(11): p. 1524–1535. https://doi.org/10.1055/s-0040-1714369 PMID: 32679593

54. Long H., et al., D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis. BioMed Research International, 2020. 2020: p. 6159720. https://doi.org/10.1155/2020/6159720 PMID: 32596339

55. Saurabh A., et al., Role of coagulation profile in predicting disease severity among patients of COVID-19. Cureus, 2021. 13(10). https://doi.org/10.7759/cureus.19124 PMID: 3485840

56. Simou E., Leonardi-Bee J., and Britton J., The effect of alcohol consumption on the risk of ARDS: a systematic review and meta-analysis. Chest, 2018. 154(1): p. 58–68. https://doi.org/10.1016/j.chest.2017.11.041 PMID: 29288645

57. Saengow U., Assanangkornchai S., and Casswell S., Alcohol: a probable risk factor of COVID-19 severity. Addiction (Abingdon, England), 2020. https://doi.org/10.1111/add.15194 PMID: 32688440

58. Simet S.M. and Sisson J.H., Alcohol’s effects on lung health and immunity. Alcohol research: current reviews, 2015. 37(2): p. 199. PMID: 26695745

59. Saitz R., Ghali W.A., and Moskowitz M.A., The impact of alcohol-related diagnoses on pneumonia outcomes. Archives of internal medicine, 1997. 157(13): p. 1446–1452. PMID: 9224223

60. Gong X., et al., Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19. BMC Infectious Diseases, 2021. 21(1): p. 549. https://doi.org/10.1186/s12879-021-06282-6 PMID: 34112084

61. Zhou F., et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 2020. 395(10229): p. 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3 PMID: 32171076

62. Leulseged T.W., et al., COVID-19 disease severity and determinants among Ethiopian patients: a study of the millennium COVID-19 care center. medRxiv, 2021: p. 2020.10.09.20209999.

63. Zhang J., et al., Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Cln Microbiol Infect, 2020. 26(6): p. 767–772. https://doi.org/10.1016/j.cmi.2020.04.012 PMID: 32304745

64. Farshbalnadi M., et al., Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors. Experimental gerontology, 2021. 154: p. 111507. https://doi.org/10.1016/j.exger.2021.111507 PMID: 34352287

65. Hull R.D., et al., Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. Archives of internal medicine, 2000. 160(2): p. 229–236. https://doi.org/10.1001/archinte.160.2.229 PMID: 10647762

66. Li X., et al., Therapeutic effect of low-molecular-weight heparin on adult sepsis: a meta-analysis. Annals of Palliative Medicine, 2021. 10(3): p. 3115–3127. https://doi.org/10.21037/apm-21-169 PMID: 33849099